Envista Holdings Corporation (NVST)
| Market Cap | 3.74B +7.9% |
| Revenue (ttm) | 2.86B +11.9% |
| Net Income | 95.00M +76.6% |
| EPS | 0.57 +84.1% |
| Shares Out | 160.62M |
| PE Ratio | 40.53 |
| Forward PE | 14.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,838,681 |
| Open | 23.69 |
| Previous Close | 23.34 |
| Day's Range | 23.11 - 23.75 |
| 52-Week Range | 18.77 - 30.42 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 30.00 (+28.92%) |
| Earnings Date | Nov 4, 2026 |
About NVST
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for NVST stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 28.92% from the latest price.
News
Envista Schedules Third Quarter 2026 Earnings Call
BREA, Calif., Oct. 6, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2026 on Wednesday, November 4, 2026.
Envista price target lowered to $26 from $29 at BMO Capital
BMO Capital analyst Vik Chopra lowered the firm’s price target on Envista (NVST) to $26 from $29 and keeps a Market Perform rating on the shares. At a conference last…
Envista price target lowered to $27 from $30 at UBS
UBS lowered the firm’s price target on Envista (NVST) to $27 from $30 and keeps a Neutral rating on the shares.
Envista Holdings Transcript: Investor Day 2026
Envista raised its medium-term financial outlook, driven by robust innovation, operational improvements, and strong execution across all business segments. Growth is supported by new product launches, digital transformation, and disciplined capital allocation, with continued focus on expanding market share and profitability.
Envista Holdings Slides: FY 2026
Envista Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 17, 2026.
Envista Holdings Transcript: 2026 Global Healthcare Conference
Leadership highlighted improved financials and market share gains, with consumables and diagnostics leading growth. China’s VBP reforms are causing short-term revenue impacts but are expected to strengthen the company’s position long-term, especially in ortho and implants.
Envista Announces Participation in Baird 2026 Global Healthcare Conference
BREA, Calif., Sept. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2026 Global Healthcare Conference.
Envista upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Envista (NVST) to Overweight from Neutral with a price target of $32, up from $29, into the investor day on September 17. The firm believes the company is…
Envista price target raised to $23 from $21 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Envista (NVST) to $23 from $21 and keeps an Equal Weight rating on the shares. Envista delivered a solid Q2 beat and…
Envista price target raised to $34 from $31 at Baird
Baird raised the firm’s price target on Envista (NVST) to $34 from $31 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results as…
Envista price target raised to $28 from $26 at Piper Sandler
Piper Sandler analyst Jason Bednar raised the firm’s price target on Envista (NVST) to $28 from $26 and keeps a Neutral rating on the shares. The firm notes the company…
Envista price target raised to $29 from $27 at Mizuho
Mizuho raised the firm’s price target on Envista (NVST) to $29 from $27 and keeps a Neutral rating on the shares.
Envista Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 5% core growth, 28% adjusted EBITDA growth, and 58% EPS growth, with strong performance across all segments and geographies. Guidance for 2026 was raised, reflecting continued momentum, robust cash flow, and margin expansion.
Envista Holdings Earnings release: Q2 2026
Envista Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Envista Holdings Slides: Q2 2026
Envista Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Envista Holdings Quarterly report: Q2 2026
Envista Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Envista Reports Second Quarter 2026 Results
BREA, Calif., Aug. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended July 3, 2026.
Envista price target raised to $26 from $25 at Piper Sandler
Piper Sandler raised the firm’s price target on Envista (NVST) to $26 from $25 and keeps a Neutral rating on the shares. Investors have been conditioned to expect beats from…
Envista to Host Investor Day on September 17, 2026
BREA, Calif., July 28, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will hold an Investor Day on Thursday, September 17, from 9:00 a.m.
Envista initiated with a Market Perform at BMO Capital
BMO Capital analyst Vik Chopra initiated coverage of Envista (NVST) with a Market Perform rating and $27 price target The company’s turnaround is real and its CEO has earned credibility,…
Envista Schedules Second Quarter 2026 Earnings Call
BREA, Calif., July 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2026 on Wednesday, August 5, 2026.
Envista price target lowered to $32 from $34 at Barclays
Barclays lowered the firm’s price target on Envista (NVST) to $32 from $34 and keeps an Overweight rating on the shares. The firm says the company’s end markets continue to…
Envista Holdings Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals passing by majority vote. A quorum was present, and no stockholder questions were submitted during the Q&A session.
Envista price target raised to $31 from $30 at Baird
Baird analyst Jeff Johnson raised the firm’s price target on Envista (NVST) to $31 from $30 and keeps an Outperform rating on the shares. The firm updated its model following…
Envista price target raised to $29 from $26 at JPMorgan
JPMorgan raised the firm’s price target on Envista (NVST) to $29 from $26 and keeps a Neutral rating on the shares.